Sareum Holdings – TYKing along steadily through the clinic

Sareum continues to make rapid progress with its clinical plans for SDC-1801 (lead TYK2/JAK1 kinase inhibitor) and has announced the dosing of first participants (Phase Ia study) just a month into receiving regulatory approval in Australia. The Phase Ia study is a randomised…

Quelle: via Google News

Schreibe einen Kommentar